Pseudomyxoma peritonei: Biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy

Annals of Surgery

Volumn 249, Issue 2, 2009, Pages 243-249

  Baratti, Dario ^a   Kusamura, Shigeki ^a   Nonaka, Daisuke ^a   Cabras, Antonello Domenico ^a   Laterza, Barbara ^a   Deraco, Marcello ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 20; CYTOKERATIN 7; MITOMYCIN C; MUCIN 2; MUCIN 5AC; TRANSCRIPTION FACTOR CDX2; ANTINEOPLASTIC AGENT; MITOMYCIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STATISTICAL ANALYSIS; SURGICAL MORTALITY; INFUSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOHISTOCHEMISTRY; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MITOMYCIN; PROGNOSIS; PSEUDOMYXOMA PERITONEI; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 61549093082     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31818eec64     Document Type: Article

References (44)

1. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69-76.
2. Brendan MJ, Cecil TD. The etiology, clinical presentation and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12:585-603.
3. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to "pseudomyxoma peritonei." Am J Surg Pathol. 1995;19:1390-1408.
4. Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol. 1999;154:1849-1855.
5. Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apoptosis and expression of p53, CD44, bcl-2. Arch Pathol Lab Med. 2002;126:837-841.
6. Nonaka D, Kusamura S, Baratti D, et al. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology. 2006;49: 381-387.
7. Chejfec G, Rieker WJ, Jablokow VR, et al. Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology. 1986;90: 202-205.
8. Yan TD, Sugarbaker PH, Brun EA. Pseudomyxoma peritonei from mucinous adenocarcinoma of the urachus. J Clin Oncol. 2006;24:4944-4946.
9. Hawes D, Robinson R, Wira R. Pseudomyxoma peritonei from metastatic colloid carcinoma of the breast. Gastrointest Radiol. 1991;16:80-82.
10. Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol. 2003;27:650-657.
11. Fernandez RN, Daly GM. Pseudomyxoma peritonei. Arch Surg. 1980;115: 409-414.
12. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Longterm patient survival with an aggressive regional approach. Ann Surg. 1994;219:112-119.
13. Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089-1103.
14. Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005; 241:300-308.
15. Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727-731.
16. Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91:304-311.
17. Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624-634.
18. Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic chemotherapy. Ann Surg. 2007;245:104-109.
19. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytore-ductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526-534.
20. Los G, Mutsaers PH, Lenglet WJ, et al. Platinum distribution in intraperito-neal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389-394.
21. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240:278-285.
22. O'Connell JT, Tomlinson JS, Roberts AA, et al. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol. 2002;161:551-564.
23. Bibi R, Pranesh N, Saunders MP, et al. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer. 2006;95:1258-1264.
24. Maheshwari V, Tsung A, Lin Y, et al. Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix. Ann Surg Oncol. 2006;13:1610-1616.
25. Logan-Collins JM, Lowy AM, Robinson-Smith TM, et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol. 2008;15:738-744.
26. Semino-Mora C, Liu H, McAvoy T, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 and MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol. 2008;15:1414-1423.
27. Oken MM, Creech RH, Tormey DC, et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649- 655.
28. Jacquet P, Jelinek JS, Chang D, et al. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg. 1995;181:530-538.
29. Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15: 49-58.
30. Esquivel JE, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther. 1998;1:321-325.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc. 1958;53:457-81.
33. Cox DR. Regression models and life tables (with discussion). JR Stat Soc B. 1972;34:187-220.
34. Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol. 2007;14:2289-2299.
35. Elias D, Laurent S, Antoun S, et al. [Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy]. Gastroenterol Clin Biol 2003;27:407-412.
36. Esquivel J, Sugarbaker PH. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg. 2001;234:198-205.
37. Bradley RF, Stewart JH, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathological analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551-559.
38. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
39. Mallo GV, Soubeyran P, Lissitzky JC, et al. Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells. J Biol Chem. 1998;273:4030-4036.
40. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078-1085.
41. Velchich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin MUC2. Science. 2002;295:1726-1729.
42. Baratti D, Kusamura S, Martinetti A, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:2300-2308.
43. Alexander-Sefre F, Chandrakumaran K, Banerjee S, et al. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis. 2005;7:382-386.
44. Fujimoto S, Takahashi M, Kobayashi K, et al. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology. 1993;50:338-343.